论文部分内容阅读
为研制新型无副作用的降血尿酸药物,在氧嗪酸钾盐诱导小鼠产生高尿酸血症模型的基础上,探讨大豆异黄酮的抗高尿酸活性。将昆明雄性小鼠随机分为6组,即正常对照组、高尿酸血症模型对照组、模型给药组(分为大豆异黄酮25,50和100 mg·kg-1剂量组、别嘌醇5 mg·kg-1剂量组)。连续7 d每天灌胃氧嗪酸钾盐(250 mg·kg-1)1 h后灌胃给药。分别测定血清尿酸、肌酐与尿素氮水平及尿液尿酸和肌酐水平。结果表明:与高尿酸血症模型组相比,大豆异黄酮显著或极显著降低高尿酸血症小鼠血清尿酸、肌酐和尿素氮水平,提高24 h尿液尿酸和肌酐排泄量以及尿酸排泄分数。综合考虑,大豆异黄酮通过促进肾脏尿酸排泄作用,从而体现抗高尿酸活性。
In order to develop a new type of hypokalemic drug without side effects, the antihyperchogenic activity of soy isoflavones was explored on the basis of the model of hyperuricemia induced by oxonic acid potassium salt in mice. Kunming male mice were randomly divided into 6 groups, namely, normal control group, hyperuricemia model control group, model group (divided into 25, 50 and 100 mg · kg-1 groups, allopurinol 5 mg · kg-1 dose group). Administration of potassium oxonic acid salt (250 mg · kg-1) for 7 days daily for 1 h followed by intragastric administration. Serum uric acid, creatinine and urea nitrogen levels and urine uric acid and creatinine were measured. The results showed that compared with hyperuricemia model group, soy isoflavones significantly or very significantly reduce serum uric acid, creatinine and urea nitrogen levels in hyperuricemic mice and increase uric acid and creatinine excretion and uric acid excretion . Taken together, soy isoflavones promote renal uric acid excretion, which reflects the anti-uric acid activity.